Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520623 | 1.00 | IDO1 (0.50) | IDO1GABRA1GABRB2TAAR1HPGD | |
| Isopropylamine SCHEMBL27806417 | 0.94 | IDO1 (0.50) | IDO1GABRA1GABRB2TAAR1HPGD | |
| SCHEMBL28334930 | 0.86 | IDO1 (0.52) | IDO1TAAR1HPGDHTTCHRM2 | |
| SCHEMBL9480536 | 0.86 | IDO1 (0.52) | IDO1TAAR1HPGDHTTCHRM2 | |
| SCHEMBL8986617 | 0.86 | SLC6A4 (0.44) | LMNAALDH1A1 | |
| SCHEMBL878976 | 0.83 | IDO1 (0.53) | IDO1GABRA1GABRB2TAAR1HPGD | |
| SCHEMBL28554357 | 0.83 | ALDH1A1 (0.49) | HPGDHTTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL24129506 | 0.82 | IDO1 (0.52) | IDO1TAAR1HPGDHTTCHRM2 | |
| SCHEMBL22623555 | 0.82 | IDO1 (0.53) | IDO1TAAR1HPGDHTTCHRM2 | |
| SCHEMBL6206376 | 0.82 | IDO1 (0.48) | IDO1TAAR1HPGDHTTCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101759576-A | Synthesis method of (R)-moprolol | ZHEJIANG MEDICINE CO LTD | 2010-06-30 | — | — | CN | claimed |
| CN-101759577-A | Synthesis method of (R)-moprolol | ZHEJIANG MEDICINE CO LTD | 2010-06-30 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| CN-105377224-B | Dyeing composition | 莱雅公司 | 2021-02-12 | — | — | CN | disclosed |
| WO-2020230132-A1 | COMPOSITIONS FOR CROP PROTECTION | AGREMATCH LTD. (IL) | 2020-11-19 | — | — | WO | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| EP-2001474-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | disclosed |
| EP-0976734-B1 | Selective inhibitors of viral or bacterial neuraminidase | GILEAD SCIENCES INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176758-A1 | 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors | GILEAD SCIENCES, INC. | 2005-08-11 | — | — | US | disclosed |
| US-6225341-B1 | FOR INHIBITING NEURAMINIDASE; FOR THERAPY AND PROPHYLAXIS OF VIRUS INFECTION | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0759917-B1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES INC (US) | 2000-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | IDO1 2526/4885GABRA1 363/4885GABRB2 450/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | IDO1 2046/4885GABRA1 1082/4885GABRB2 1376/4885 |
| US-20050176758-A1 | 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors | NEU3, NEU1, NEU4 | IDO1 496/4885GABRA1 2560/4885GABRB2 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.